Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-emptive cefazolin for reducing septic complications in high-risk compound skull fractures
PACTR202402715350374Not yet recruiting
- Start
- May 2024
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cefazolin in skull fracture, sponsored by None. Primary endpoint: Incidence of septic complications. Planned start May 2024; status: not yet recruiting.
02
Drugs
cefazolin
03
Conditions
skull fracture
Beyond the preview
Go deeper on PACTR202402715350374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202402715350374.